04Sep/13

1000 Delhi students walk to create awareness about organ donation – India.Com Health

1000 Delhi students walk to create awareness about organ donation
India.Com Health
Around 1,000 students of Shivaji College in Delhi organised a walkathon Wednesday to create awareness on organ donation. ‘We are the first college under Delhi University to organise an awareness campaign on organ donation. In India, 20 people die 
Organ donation campaign by Shivaji CollegeTimes of India

all 2 news articles »

04Sep/13

Noble's Hospital 'ahead of the game' with tackling Acute Kidney Injury – isleofman.com

Noble’s Hospital ‘ahead of the game’ with tackling Acute Kidney Injury
isleofman.com
The National Institute for Health and Care Excellence (NICE) in the UK last week flagged concerns that 12,000 lives a year could be saved in England by taking simple steps to avoid or properly identify and treat Acute Kidney Injury (AKI) in patients
Measuring glomerular filtration rate in the intensive care unit: no 7thSpace Interactive (press release)
Better kidney care could save thousands of livesWetherby Today
Kidney Care Partners announces chairman electNephrologyNews.com

all 4 news articles »

04Sep/13

Engineered Antibodies Market to be Worth USD 5.7 Billion by 2023: Report by … – PharmiWeb.com (press release)

Engineered Antibodies Market to be Worth USD 5.7 Billion by 2023: Report by
PharmiWeb.com (press release)
Roots Analysis has announced the addition of the “Fc Protein and Glycoengineered Antibodies Market 2013-2023” report to their offering. The report provides an extensive study of this emerging field including detailed sales forecast (till 2023) of

and more »

04Sep/13

Phase III Clinical Study Data Demonstrating LCP-Tacro(TM)'s Comparable … – MarketWatch (press release)

Phase III Clinical Study Data Demonstrating LCP-Tacro(TM)’s Comparable
MarketWatch (press release)
HORSHOLM, Denmark, Sept. 4, 2013 /PRNewswire via COMTEX/ — Veloxis Pharmaceuticals A/S (omx:VELO) today announced that data from the 3002, randomized, double-blind, double-dummy, Phase III study in 543 de novo kidney transplant patients will 

and more »